Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Jennifer M. Connelly MD

Jennifer M. Connelly MD profile photo picture

Professor

Institution: Medical College of Wisconsin
Department: Neurology
Division: General
Program: Neuro-Oncology

Member of the Cancer Center
Member of the Wisconsin Institute of NeuroScience (WINS)

View Curriculum Vitae

Clinical Expertise

  • Brain Neoplasms
  • Brain Stem Neoplasms
  • Diffusion Magnetic Resonance Imaging
  • Glioblastoma
  • Glioma
  • Hamartoma Syndrome, Multiple
  • Li-Fraumeni Syndrome
  • Neurofibromatosis 1
  • Neurofibromatosis 2
  • Tuberous Sclerosis

    • Leadership Positions

  • Co-Director of the Neuro-Oncology Program

    • Publications (44)

  • Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting. (Riegel DC, Bureau BL, Conlon P, Chavez G, Connelly JM) J Neurooncol 2025 May;173(1):49-57 PMID: 40163248 PMCID: PMC12040967 SCOPUS ID: 2-s2.0-105001514823 03/31/2025    
  • Radio-pathomic estimates of cellular growth kinetics predict survival in recurrent glioblastoma. (Oshima S, Yao J, Bobholz S, Nagaraj R, Raymond C, Teraishi A, Guenther AM, Kim A, Sanvito F, Cho NS, Eldred BSC, Connelly JM, Nghiemphu PL, Lai A, Salamon N, Cloughesy TF, LaViolette PS, Ellingson BM) CNS Oncol 2024 Dec 31;13(1):2415285 PMID: 39535237 PMCID: PMC11562955 SCOPUS ID: 2-s2.0-85209813692 11/13/2024    
  • Mesenchymal-Type Genetic Mutations Are Likely Prerequisite for Glioblastoma Multiforme to Metastasize Outside the Central Nervous System: An Original Case Series and Systematic Review of the Literature. (Laurin BJ, Treffy R, Connelly JM, Straza M, Mueller WM, Krucoff MO) World Neurosurg 2025 Jan;193:397-426 PMID: 39419169 SCOPUS ID: 2-s2.0-85208505671 10/18/2024    
  • Treatment of Extraneural Metastases of Myxopapillary Ependymomas With Dose-Dense Temozolomide and Lapatinib. (Riegel DC, Fonkem E, Connelly JM) Cureus 2024 Aug;16(8):e67928 PMID: 39193057 PMCID: PMC11348868 08/28/2024    
  • Noninvasive Autopsy-Validated Tumor Probability Maps Identify Glioma Invasion Beyond Contrast Enhancement. (Bobholz SA, Lowman AK, Connelly JM, Duenweg SR, Winiarz A, Nath B, Kyereme F, Brehler M, Bukowy J, Coss D, Lupo JM, Phillips JJ, Ellingson BM, Krucoff MO, Mueller WM, Banerjee A, LaViolette PS) Neurosurgery 2024 Sep 01;95(3):537-547 PMID: 38501824 PMCID: PMC11302944 SCOPUS ID: 2-s2.0-85201436914 03/19/2024       1 Citation
  • Correction to: Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response. (Bobholz SA, Hoefs A, Hamburger J, Lowman AK, Winiarz A, Duenweg SR, Kyereme F, Connelly J, Coss D, Krucoff M, Banerjee A, LaViolette PS) J Neurooncol 2024 Apr;167(2):243 PMID: 38498261 PMCID: PMC11023959 SCOPUS ID: 2-s2.0-85187929260 03/19/2024    
  • Radio-pathomic maps of glioblastoma identify phenotypes of non-enhancing tumor infiltration associated with bevacizumab treatment response. (Bobholz SA, Hoefs A, Hamburger J, Lowman AK, Winiarz A, Duenweg SR, Kyereme F, Connelly J, Coss D, Krucoff M, Banerjee A, LaViolette PS) J Neurooncol 2024 Apr;167(2):233-241 PMID: 38372901 PMCID: PMC11024025 SCOPUS ID: 2-s2.0-85185314152 02/19/2024       5 Citations
  • Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma. (Al-Gizawiy MM, Wujek RT, Alhajala HS, Cobb JM, Prah MA, Doan NB, Connelly JM, Chitambar CR, Schmainda KM) Front Oncol 2023;13:1278157 PMID: 38288102 PMCID: PMC10822938 SCOPUS ID: 2-s2.0-85183616626 01/30/2024       3 Citations
  • Cystic Brain Metastasis Outcomes After Gamma Knife Radiation Therapy. (Amidon RF, Livingston K, Kleefisch CJ, Martens M, Straza M, Puckett L, Schultz CJ, Mueller WM, Connelly JM, Noid G, Morris K, Bovi JA) Adv Radiat Oncol 2024 Jan;9(1):101304 PMID: 38260234 PMCID: PMC10801666 SCOPUS ID: 2-s2.0-85167453267 01/23/2024    
  • Cystic Brain Metastasis Outcomes After Gamma Knife Radiation Therapy (Amidon RF, Livingston K, Kleefisch CJ, Martens M, Straza M, Puckett L, Schultz CJ, Mueller WM, Connelly JM, Noid G, Morris K, Bovi JA) Advances in Radiation Oncology January 2024;9(1) SCOPUS ID: 2-s2.0-85167453267 01/01/2024    
  • Magnetic resonance imaging-derived relative cerebral blood volume characteristics in a case of pathologically confirmed neurocysticercosis: illustrative case. (Botros NE, Polinger-Hyman D, Beck RT, Kleefisch C, Mrachek EKS, Connelly J, Schmainda KM, Krucoff MO) J Neurosurg Case Lessons 2023 Dec 18;6(25) PMID: 38109728 PMCID: PMC10732321 SCOPUS ID: 2-s2.0-85185333375 12/18/2023    
  • Symptomatic radionecrosis after postoperative but not preoperative stereotactic radiosurgery in a single patient: illustrative case. (Laurin BJ, Straza M, Noid G, Connelly JM, Mueller WM, Bovi J, Krucoff MO) J Neurosurg Case Lessons 2023 Oct 16;6(16) PMID: 37870754 PMCID: PMC10584084 SCOPUS ID: 2-s2.0-85174582314 10/23/2023    
  • Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma. (Amidon RF, Santos-Pinheiro F, Straza M, Prah MA, Mueller WM, Krucoff MO, Connelly JM, Kleefisch CJ, Coss DJ, Cochran EJ, Bovi JA, Schultz CJ, Schmainda KM) Front Oncol 2022;12:1066191 PMID: 36561526 PMCID: PMC9763264 SCOPUS ID: 2-s2.0-85144231369 12/24/2022       3 Citations
  • Glioma progression is shaped by genetic evolution and microenvironment interactions. (Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, Wöehrer A, Aldape K, Ismail A, Sivajothi SK, Barthel FP, Kim H, Kocakavuk E, Ahmed N, White K, Datta I, Moon HE, Pollock S, Goldfarb C, Lee GH, Garofano L, Anderson KJ, Nehar-Belaid D, Barnholtz-Sloan JS, Bakas S, Byrne AT, D'Angelo F, Gan HK, Khasraw M, Migliozzi S, Ormond DR, Paek SH, Van Meir EG, Walenkamp AME, Watts C, Weiss T, Weller M, Palucka K, Stead LF, Poisson LM, Noushmehr H, Iavarone A, Verhaak RGW, GLASS Consortium) Cell 2022 Jun 09;185(12):2184-2199.e16 PMID: 35649412 PMCID: PMC9189056 SCOPUS ID: 2-s2.0-85131903367 06/02/2022       240 Citations
  • Radio-Pathomic Maps of Cell Density Identify Brain Tumor Invasion beyond Traditional MRI-Defined Margins. (Bobholz SA, Lowman AK, Brehler M, Kyereme F, Duenweg SR, Sherman J, McGarry SD, Cochran EJ, Connelly J, Mueller WM, Agarwal M, Banerjee A, LaViolette PS) AJNR Am J Neuroradiol 2022 May;43(5):682-688 PMID: 35422419 PMCID: PMC9089258 SCOPUS ID: 2-s2.0-85130001814 04/16/2022       16 Citations
  • Basal Ganglia Iron Content Increases with Glioma Severity Using Quantitative Susceptibility Mapping: A Potential Biomarker of Tumor Severity. (Reith TP, Prah MA, Choi EJ, Lee J, Wujek R, Al-Gizawiy M, Chitambar CR, Connelly JM, Schmainda KM) Tomography 2022 Mar 15;8(2):789-797 PMID: 35314642 PMCID: PMC8938779 SCOPUS ID: 2-s2.0-85126905772 03/23/2022       8 Citations
  • Adrenocorticotropic Hormone Secreting Pituitary Carcinoma: Rare, Durable Response to Concurrent Chemotherapy and Reirradiation With a Review of the Literature (Orr M, Findling J, Zwagerman N, Connelly J, Albano K, Bovi J) Advances in Radiation Oncology 1 March 2022;7(2) SCOPUS ID: 2-s2.0-85119325950 03/01/2022       2 Citations
  • Magnetic Resonance Imaging Mapping of Brain Tumor Burden: Clinical Implications for Neurosurgical Management: Case Report. (Connelly JM, Prah MA, Santos-Pinheiro F, Mueller W, Cochran E, Schmainda KM) Neurosurg Open 2021 Dec;2(4):okab029 PMID: 34661110 PMCID: PMC8508085 10/19/2021    
  • Sudden Paralysis in a 39-Year-Old Woman With Metastatic Breast Cancer. (Griffiths C, Connelly J, Chaudhary LN) JAMA Oncol 2021 Aug 01;7(8):1239-1240 PMID: 34042938 SCOPUS ID: 2-s2.0-85107333574 05/28/2021       1 Citation
  • Quantitative analysis of Alzheimer's disease pathology in glioblastoma patients (Brehler M, Lowman AK, Bobholz S, McGarry SD, Connelly J, Cochran E, Laviolette PS) Progress in Biomedical Optics and Imaging - Proceedings of SPIE 2021;11603 SCOPUS ID: 2-s2.0-85103234952 01/01/2021    
  • Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes. (Bovi JA, Prah MA, Retzlaff AA, Schmainda KM, Connelly JM, Rand SD, Marszalkowski CS, Mueller WM, Siker ML, Schultz CJ) Int J Radiat Oncol Biol Phys 2020 Nov 15;108(4):979-986 PMID: 32599030 PMCID: PMC8655709 SCOPUS ID: 2-s2.0-85089292279 07/01/2020       20 Citations
  • Radiomic Features of Multiparametric MRI Present Stable Associations With Analogous Histological Features in Patients With Brain Cancer. (Bobholz SA, Lowman AK, Barrington A, Brehler M, McGarry S, Cochran EJ, Connelly J, Mueller WM, Agarwal M, O'Neill D, Nencka AS, Banerjee A, LaViolette PS) Tomography 2020 Jun;6(2):160-169 PMID: 32548292 PMCID: PMC7289245 SCOPUS ID: 2-s2.0-85086686895 06/18/2020       33 Citations
  • NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma. (Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raizer JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, Wagle N, Merrell RT, Wendland MM, Mehta MP) Cancer 2020 Jun 15;126(12):2821-2828 PMID: 32154928 PMCID: PMC7245544 SCOPUS ID: 2-s2.0-85081276146 03/11/2020       27 Citations
  • Longitudinal molecular trajectories of diffuse glioma in adults. (Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW, GLASS Consortium) Nature 2019 Dec;576(7785):112-120 PMID: 31748746 PMCID: PMC6897368 SCOPUS ID: 2-s2.0-85075234677 11/22/2019       369 Citations
  • High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature. (Kapke JT, Schneidewend RJ, Jawa ZA, Huang CC, Connelly JM, Chitambar CR) Hematol Oncol Stem Cell Ther 2019 Dec;12(4):189-193 PMID: 31629723 SCOPUS ID: 2-s2.0-85075443191 10/21/2019       28 Citations
  • Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors. (Schmainda KM, Prah MA, Hu LS, Quarles CC, Semmineh N, Rand SD, Connelly JM, Anderies B, Zhou Y, Liu Y, Logan B, Stokes A, Baird G, Boxerman JL) AJNR Am J Neuroradiol 2019 Apr;40(4):626-633 PMID: 30923088 PMCID: PMC6461489 SCOPUS ID: 2-s2.0-85064588009 03/30/2019       41 Citations
  • Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency. (Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP) Oncotarget 2017 Dec 22;8(68):112662-112674 PMID: 29348854 PMCID: PMC5762539 SCOPUS ID: 2-s2.0-85038823142 01/20/2018       56 Citations
  • Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. (Prah MA, Al-Gizawiy MM, Mueller WM, Cochran EJ, Hoffmann RG, Connelly JM, Schmainda KM) J Neurooncol 2018 Jan;136(1):13-21 PMID: 28900832 PMCID: PMC5756123 SCOPUS ID: 2-s2.0-85029185195 09/14/2017       39 Citations
  • Acid ceramidase confers radioresistance to glioblastoma cells. (Doan NB, Nguyen HS, Al-Gizawiy MM, Mueller WM, Sabbadini RA, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP) Oncol Rep 2017 Oct;38(4):1932-1940 PMID: 28765947 PMCID: PMC5652937 SCOPUS ID: 2-s2.0-85029804998 08/03/2017       41 Citations
  • Acid ceramidase is a novel drug target for pediatric brain tumors. (Doan NB, Nguyen HS, Montoure A, Al-Gizawiy MM, Mueller WM, Kurpad S, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP) Oncotarget 2017 Apr 11;8(15):24753-24761 PMID: 28445970 PMCID: PMC5421885 SCOPUS ID: 2-s2.0-85017541087 04/28/2017       29 Citations
  • Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. (Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N) BMC Cancer 2016 Nov 04;16(1):842 PMID: 27809808 PMCID: PMC5096303 SCOPUS ID: 2-s2.0-84994355377 11/05/2016       13 Citations
  • A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. (Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, Damek D, Bota DA, Connelly J) CNS Oncol 2017 Jan;6(1):29-43 PMID: 27628854 PMCID: PMC6027938 SCOPUS ID: 2-s2.0-85050579311 09/16/2016       38 Citations
  • Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma. (Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS) AJNR Am J Neuroradiol 2016 Dec;37(12):2201-2208 PMID: 27492073 PMCID: PMC5161572 SCOPUS ID: 2-s2.0-85006469905 08/06/2016       66 Citations
  • Location of brain tumor intersecting white matter tracts predicts patient prognosis. (Mickevicius NJ, Carle AB, Bluemel T, Santarriaga S, Schloemer F, Shumate D, Connelly J, Schmainda KM, LaViolette PS) J Neurooncol 2015 Nov;125(2):393-400 PMID: 26376654 PMCID: PMC6094943 SCOPUS ID: 2-s2.0-84945477926 09/18/2015       29 Citations
  • Photodynamic therapy (PDT) for malignant brain tumors--where do we stand? (Quirk BJ, Brandal G, Donlon S, Vera JC, Mang TS, Foy AB, Lew SM, Girotti AW, Jogal S, LaViolette PS, Connelly JM, Whelan HT) Photodiagnosis Photodyn Ther 2015 Sep;12(3):530-44 PMID: 25960361 SCOPUS ID: 2-s2.0-84940900716 05/12/2015       190 Citations
  • Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma. (LaViolette PS, Mickevicius NJ, Cochran EJ, Rand SD, Connelly J, Bovi JA, Malkin MG, Mueller WM, Schmainda KM) Neuro Oncol 2014 Dec;16(12):1599-606 PMID: 25059209 PMCID: PMC4232087 SCOPUS ID: 2-s2.0-84938693563 07/26/2014       67 Citations
  • Comprehensive characterization of glioblastoma tumor tissues for biomarker identification using mass spectrometry-based label-free quantitative proteomics. (Heroux MS, Chesnik MA, Halligan BD, Al-Gizawiy M, Connelly JM, Mueller WM, Rand SD, Cochran EJ, LaViolette PS, Malkin MG, Schmainda KM, Mirza SP) Physiol Genomics 2014 Jul 01;46(13):467-81 PMID: 24803679 PMCID: PMC4587597 SCOPUS ID: 2-s2.0-84903603535 05/08/2014       39 Citations
  • Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. (Schmainda KM, Prah M, Connelly J, Rand SD, Hoffman RG, Mueller W, Malkin MG) Neuro Oncol 2014 Jun;16(6):880-8 PMID: 24431219 PMCID: PMC4022214 SCOPUS ID: 2-s2.0-84901024226 01/17/2014       107 Citations
  • Effects of perfusion on diffusion changes in human brain tumors. (Cohen AD, LaViolette PS, Prah M, Connelly J, Malkin MG, Rand SD, Mueller WM, Schmainda KM) J Magn Reson Imaging 2013 Oct;38(4):868-75 PMID: 23389889 PMCID: PMC3735792 SCOPUS ID: 2-s2.0-84886901290 02/08/2013       6 Citations
  • Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. (LaViolette PS, Cohen AD, Prah MA, Rand SD, Connelly J, Malkin MG, Mueller WM, Schmainda KM) Neuro Oncol 2013 Apr;15(4):442-50 PMID: 23382287 PMCID: PMC3607265 SCOPUS ID: 2-s2.0-84875717479 02/06/2013       42 Citations
  • Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI. (Ellingson BM, LaViolette PS, Rand SD, Malkin MG, Connelly JM, Mueller WM, Prost RW, Schmainda KM) Magn Reson Med 2011 Apr;65(4):1131-43 PMID: 21413079 PMCID: PMC3065939 SCOPUS ID: 2-s2.0-79952781642 03/18/2011       38 Citations
  • Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas. (Ellingson BM, Malkin MG, Rand SD, LaViolette PS, Connelly JM, Mueller WM, Schmainda KM) J Neurooncol 2011 Mar;102(1):95-103 PMID: 20798977 PMCID: PMC3033973 SCOPUS ID: 2-s2.0-79952194217 08/28/2010       56 Citations
  • Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. (Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, Bedekar DP, Schmainda KM) J Magn Reson Imaging 2010 Mar;31(3):538-48 PMID: 20187195 PMCID: PMC2903058 SCOPUS ID: 2-s2.0-77649224700 02/27/2010       224 Citations
  • Environmental risk factors for brain tumors. (Connelly JM, Malkin MG) Curr Neurol Neurosci Rep 2007 May;7(3):208-14 PMID: 17488586 SCOPUS ID: 2-s2.0-34249717736 05/10/2007       75 Citations
    • Last update: 04/26/2025